Aurobindo Pharma: CLSA downgrades Aurobindo Pharma to Hold with a Target Price of ₹1490 (raised), citing an in-line quarter with strong Europe growth offsetting weak US sales, margin pressure from higher opex, and expectations of future growth from launches, portfolio expansion and acquisitions, though meaningful benefits are likely only from FY28.

 25 May 2026 08:50 AM

Aurobindo Pharma: CLSA downgrades Aurobindo Pharma to Hold with a Target Price of ₹1490 (raised), citing an in-line quarter with strong Europe growth offsetting weak US sales, margin pressure from higher opex, and expectations of future growth from launches, portfolio expansion and acquisitions, though meaningful benefits are likely only from FY28.

Aurobindo Pharma: BofA Securities maintains a Buy on Aurobindo Pharma with a Target Price of ₹1700, citing stable EBITDA and margin expansion driven by Pen-G plant ramp-up despite weaker US sales, while management’s 21% margin guidance and potential US revenue boost from the Lannett deal remain key positives.

 25 May 2026 08:51 AM

Aurobindo Pharma: BofA Securities maintains a Buy on Aurobindo Pharma with a Target Price of ₹1700, citing stable EBITDA and margin expansion driven by Pen-G plant ramp-up despite weaker US sales, while management’s 21% margin guidance and potential US revenue boost from the Lannett deal remain key positives.

Aurobindo Pharma: Goldman Sachs maintains a Buy on Aurobindo Pharma with a Target Price of ₹1550, citing broadly in-line Q4 results driven by strong Europe and growth market performance offsetting weaker US sales from gRevlimid ramp-down, while expecting high single-digit topline growth and 21%+ EBITDA margins in FY27.

 25 May 2026 08:53 AM

Aurobindo Pharma: Goldman Sachs maintains a Buy on Aurobindo Pharma with a Target Price of ₹1550, citing broadly in-line Q4 results driven by strong Europe and growth market performance offsetting weaker US sales from gRevlimid ramp-down, while expecting high single-digit topline growth and 21%+ EBITDA margins in FY27.

Aurobindo Pharma: DAM Capital maintains a Buy on Aurobindo Pharma with a Target Price of ₹1767, citing consistent operating performance, strong positioning to benefit from generic industry tailwinds, investments in biosimilars and injectables, value-accretive Lannett acquisition, and expected gains from major capex projects with easing capex intensity ahead.

 25 May 2026 08:53 AM

Aurobindo Pharma: DAM Capital maintains a Buy on Aurobindo Pharma with a Target Price of ₹1767, citing consistent operating performance, strong positioning to benefit from generic industry tailwinds, investments in biosimilars and injectables, value-accretive Lannett acquisition, and expected gains from major capex projects with easing capex intensity ahead.

Aurobindo Pharma: Nuvama maintains a Buy on Aurobindo Pharma with a Target Price of ₹1680, citing in-line revenue and EBITDA with strong Europe and growth market performance offsetting weak US growth, while expecting operating leverage benefits from Pen-G and TheraNym CMO along with gains from Europe growth and the Lannett deal closure.

 25 May 2026 08:53 AM

Aurobindo Pharma: Nuvama maintains a Buy on Aurobindo Pharma with a Target Price of ₹1680, citing in-line revenue and EBITDA with strong Europe and growth market performance offsetting weak US growth, while expecting operating leverage benefits from Pen-G and TheraNym CMO along with gains from Europe growth and the Lannett deal closure.

Aurobindo Pharma: New Unit Arrow Pharma Production SAS Launched In France To Boost Generic Manufacturing, Fully Owned With Authorized Capital Of 100,000 EUR.

 22 May 2026 12:35 PM

Aurobindo Pharma: New Unit Arrow Pharma Production SAS Launched In France To Boost Generic Manufacturing, Fully Owned With Authorized Capital Of 100,000 EUR.

Aurobindo Pharma: Sets Margin Expectations Above 21% For FY27 - CNBC TV18

 22 May 2026 10:14 AM

Aurobindo Pharma: Sets Margin Expectations Above 21% For FY27 - CNBC TV18

AUROBINDO PHARMA: Q4 CONS NET PROFIT 9.2B RUPEES VS 9.03B (YOY) || Q4 REVENUE 87.5B RUPEES VS 83.8B (YOY)

 21 May 2026 08:09 PM

AUROBINDO PHARMA: Q4 CONS NET PROFIT 9.2B RUPEES VS 9.03B (YOY) || Q4 REVENUE 87.5B RUPEES VS 83.8B (YOY)

AUROBINDO PHARMA: Q4 EBITDA 17.6B RUPEES VS 19B (YOY) || Q4 EBITDA MARGIN 20.20% VS 22.98% (YOY)

 21 May 2026 08:09 PM

AUROBINDO PHARMA: Q4 EBITDA 17.6B RUPEES VS 19B (YOY) || Q4 EBITDA MARGIN 20.20% VS 22.98% (YOY)

Aurobindo Pharma: Co subsidiary CuraTeQ Biologics receives CDSCO marketing authorisation (Form CT 23) for Bevqolva® (bevacizumab biosimilar).

 16 May 2026 11:13 AM

Aurobindo Pharma: Co subsidiary CuraTeQ Biologics receives CDSCO marketing authorisation (Form CT 23) for Bevqolva® (bevacizumab biosimilar).

Aurobindo Pharma Ltd: Unit-VII Gets "Voluntary Action Indicated" Status From US FDA; 9 Observations Found.

 06 May 2026 09:12 AM

Aurobindo Pharma Ltd: Unit-VII Gets "Voluntary Action Indicated" Status From US FDA; 9 Observations Found.

Aurobindo Pharma Ltd: Plans To Buy Up To 26% Of Swarnaakshu Solar Power Private Limited, Pending State Government Approval By March 31, 2026.

 30 Dec 2025 11:17 AM

Aurobindo Pharma Ltd: Plans To Buy Up To 26% Of Swarnaakshu Solar Power Private Limited, Pending State Government Approval By March 31, 2026.